Navigation Links
AAHIVM Encouraged by TMC125 Approval
Date:2/4/2008

New HIV Medication Could Offer More Options for Treatment-Experienced

Patients

WASHINGTON, Feb. 4 /PRNewswire/ -- The American Academy of HIV Medicine (AAHIVM), a national organization of HIV-treating physicians, nurse practitioners and physician assistants, praised the accelerated U.S. Food and Drug Administration (FDA) approval of the anti-HIV medication TMC125 (etravirine), the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be introduced in nearly 10 years, and the first to show antiviral activity in treatment-experienced adult patients with NNRTI-resistant virus. NNRTI drug resistance occurs when HIV develops mutations that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness.

"With the FDA's accelerated approval of TMC125, we are encouraged by the increased treatment options that are now available for our patients," said AAHIVM Board Chair Jeffrey Schouten, MD, AAHIVS. "With antiretroviral therapy now in its third decade, HIV care providers have increasing concern over the cross-resistance of the NNRTI class. A patient resistant to one NNRTI is generally resistant to the other NNRTIs available, which significantly limits our options with our longtime and treatment-experienced patients. This drug may also be very useful for people who are infected with an NNRTI-resistant strain of HIV which is not uncommon. TMC125 offers HIV care providers another treatment option that could dramatically increase the capacity for continued success in their patients' long-term HIV care."

FDA-accelerated approval procedures allow for earlier approval of drugs that provide a meaningful therapeutic advantage over existing treatment for serious or life-threatening diseases. Longer-term data will be required before the FDA can consider traditional approval of TMC125. Dr. Schouten emphasized the importance of closely monitoring changes to any treatment regimen to recognize possible barriers to treatment adherence and to maximize potential for treatment success.

The American Academy of HIV Medicine is an independent organization of AAHIVM HIV Specialists(TM) and other health care professionals dedicated to advancing excellence in HIV/AIDS care. Through advocacy and education, AAHIVM is committed to supporting HIV clinicians and to ensuring better care for those living with HIV disease. AAHIVM is the only U.S. medical organization serving a membership of MDs, DOs, NPs and PAs, and providing all members the opportunity to credential as HIV Specialists(TM).


'/>"/>
SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink
2. Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking
3. New York City Cancer Patients, Survivors and Care Givers Encouraged to Keep Going(R)
4. Radiologists encouraged to look beyond cancer for clinically unseen diseases
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
7. Researchers query FDA about updating requirements for drug approval
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. ATS Medical Provides Update on First Generation Tissue Valve Approval
10. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
11. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY ... announced that Mercy Medical Center will serve as the official title sponsor of the ... Sunday, June 25, 2017, thousands of women will walk or run the course around ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special ... $29.97; for the remaining days of March, the price will be only $19.97. The ... price of just $10 (regular retail price $19.97). , The special promotional prices are ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wall Centre Dental team is ... from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain veneers, ... esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton Reskovich ...
(Date:3/29/2017)... Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... patients on early orthodontic treatment and accepting new pediatric patients, with or without a ... help young patients have a better orthodontic outcome and experience. When patients receive early ...
(Date:3/29/2017)... ... 2017 , ... Altima Technologies, Inc., the maker of popular ... assets and audio-video devices has recently updated its Visio Stencils library with new ... download shapes and stencils from http://www.VisioStencils.com. , New devices were added ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global energy-based aesthetic devices market to ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused company ... announced that Carmine N. Stengone , president and chief executive ... & Company 16 th Annual Healthcare Conference on Wednesday, April ... Westin Grand Central Hotel in New York City ... ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology: